Urology Care Foundation Announces Recipient of the 2025 Rising Stars in Urology Research Award

Urology Care Foundation Announces Recipient of the 2025 Rising Stars in Urology Research Award Dr. de Carvalho’s research ...
MedPage Today on MSN

First-Line Bladder Cancer Trial Makes the Case for HER2 Screening

The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...

Blood test guides post-surgical immunotherapy for muscle-invasive bladder cancer

Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the ...

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients …

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...
Le Lézard

CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO

CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today presented compelling primary results from the Phase 2 GDFATHER-NEO trial in an oral late-breaking session at the European ...

IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.